Stock listing
BBOT Stock Price, News, Filings & Events — Bridgebio Oncology Therapeutics, Inc.
Selected listing: BBOT · BOATS · USD · US
This page tracks Bridgebio Oncology Therapeutics, Inc.'s BBOT:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BBOT:BOATS. BBOT:BOATS is the stock-level entry point for investors researching Bridgebio Oncology Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Bridgebio Oncology Therapeutics, Inc. is a public company listed under the ticker BBOT, operating in the American market. The company focuses on developing innovative therapies for cancer treatment. As of now, Bridgebio has a market capitalization of approximately $666.5 million.

- Ticker
- BBOT:BOATS
- Asset type
- Stock
- Market cap
- $396.9M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Bridgebio Oncology Therapeutics, Inc. BBOT:BOATS stock context
This page tracks Bridgebio Oncology Therapeutics, Inc.'s BBOT:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BBOT:BOATS. BBOT:BOATS is the stock-level entry point for investors researching Bridgebio Oncology Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Bridgebio Oncology Therapeutics, Inc. is a public company listed under the ticker BBOT, operating in the American market. The company focuses on developing innovative therapies for cancer treatment. As of now, Bridgebio has a market capitalization of approximately $666.5 million.
Latest news from Bridgebio Oncology Therapeutics, Inc.
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 11, 2026
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 12, 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Model...
April 22, 2026
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meet...
April 21, 2026
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ducta...
April 20, 2026
Research Bridgebio Oncology Therapeutics, Inc.
Bridgebio Oncology Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for BBOT:BOATS.
Bridgebio Oncology Therapeutics, Inc. company profile
View the public company page for Bridgebio Oncology Therapeutics, Inc. on 6ix.
Bridgebio Oncology Therapeutics, Inc. news
Read company news and market updates connected to Bridgebio Oncology Therapeutics, Inc..
Bridgebio Oncology Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Bridgebio Oncology Therapeutics, Inc..